SATELLITE SESSION:
In July 2022, WHO issued guidelines recommending the use of injectable cabotegravir as PrEP (CAB PrEP) for HIV and PEPFAR’s 2023 COP guidance encourages countries to begin planning for its rollout. While CAB PrEP is not yet approved for use in Asia, applications for regulatory approval have been submitted in China, Malaysia, Myanmar, Philippines, Thailand, and Vietnam. To expedite CAB PrEP’s availability and optimize impact, community preferences and potential access barriers must be well understood and addressed collaboratively by all stakeholders. This IAS 2023 session will review evidence from recent studies designed to inform CAB PrEP introduction in Asia; identify regional priorities for a CAB implementation science agenda; examine regional lessons from oral PrEP introduction and scale-up; highlight progress and lessons from preparing for CAB rollout in Africa; and introduce available policy and program planning tools and resources to help countries prepare for CAB rollout.

WHEN/WHERE:
Sunday, 23 July, 3:00 – 4:30 pm AEST
Boulevard Auditorium / Channel 7

HOSTED BY:
EpiC Project
MOSAIC Project
Institute of HIV Research and Innovation
WHO
UNAIDS

RELATED RESOURCES:
CAB PrEP product page
CAB PrEP training toolkit from RISE
HIV Prevention Ambassador Training Package and Toolkit
HIV Prevention User Journey Tool
CAB PrEP template guidelines from MOSAIC
Introduction research – PrEP Learning Network webinar presentation and recording
EpiC CAB PrEP advocacy tools for men who have sex with men and transgender people in the Asia-Pacific region